Effects on Coagulation of Levonorgestrel- and Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study

Summary

Combined oral contraceptives (OC) are known to increase the risk of venous thromboembolism. The aim of this randomized, cycle-controlled, cross-over study in 28 healthy volunteers was to assess potential differences between the effects of an OC containing 150 µg levonorgestrel (as representative of the so-called second generation OC) and an OC containing 150 µg desogestrel (as representative of the third generation OC) in combination with 30 µg ethinylestradiol on several coagulation factors and markers of thrombin formation. All participants used each OC for two cycles, and were switched to the other OC after a washout period of two menstrual cycles. The plasma concentrations of factors II, VII, X, and fibrinogen significantly increased during use of both the levonorgestrel- and desogestrel-containing OC’s. The plasma concentrations of factor VIII increased, and of factor V decreased, changes which only reached statistical significance during the use of the desogestrel-containing OC. During exposure to the desogestrel-containing OC, as compared with the levonorgestrel-containing OC, both factor VII and factor II showed a greater increase (FVII: 32% and 12% respectively; p <0.0001; FII: 16% and 12% respectively; p = 0.048), whereas factor V showed a greater decrease (–11% and –3% respectively; p = 0.010). Only one of the markers for ongoing coagulation (prothrombin fragment 1+2) showed a significant increase during OC use, whereas concentrations of thrombin-antithrombin complexes and soluble fibrin remained unchanged. For these markers, there was no difference between the tested OC’s. We conclude that there are differences between the effects of levonorgestrel and desogestrel-containing OC’s on some coagulation factors. Whether these changes provide a biological explanation for the reported differences in venous thromboembolic risk is as yet unclear. The real challenge now becomes to define a pattern of changes in the various systems which, if affected simultaneously, may tip the hemostatic balance towards a prethrombotic state and may lead to overt clinical venous thromboembolism.

Keywords

Oral contraceptives - coagulation - factor VII - factor II - factor V

• References

• 1 Sartwell PE, Masi AT, Arhes FDG, Green GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J Epidemiol 1969; 90: 365-80.
• 2 Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. BMJ 1980; 280: 1157-61.
• 3 Bottiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; 01: 1097-101.
• 4 Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133 (01) 32-7.
• 5 Anonymous. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346 8990 1575-82.
• 6 Anonymous. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1582-8.
• 7 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346 8990 1589-93.
• 8 Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312 7023 83-8.
• 9 Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-8.
• 10 Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5-13.
• 11 Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349 9045 83-8.
• 12 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78 (01) 315-26.
• 13 Hoekema L, Nicolaes GA, Hemker HC, Tans G, Rosing J. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. Biochemistry 1997; 36 (11) 3331-5.
• 14 Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255 (01) 274-83.
• 15 Rakoczi I, Gero G, Demeter J, Gati I. Comparative metabolic effects of oral contraceptive preparations containing different progestagens Effects of desogestrel + ethinylestradiol on the haemostatic balance. Arzneimittel-Forschung 1985; 35 (03) 630-3.
• 16 Prasad RNV, Koh S, Ratnam SS. Effects of three types of combined oral contraceptive pills on blood coagulation, fibrinolysis and platelet function. Contraception 1989; 39 (04) 369-83.
• 17 Robinson GE, Bounds W, Mackie IJ, Stocks J, Burren T, Machin SJ, Guillebaud J. Changes in metabolism induced by oral contraceptives containing desogestrel and gestodene in older women. Contraception 1990; 42 (03) 263-73.
• 18 Bloemenkamp KW, Gevers JALeuven, Helmerhorst FM, Dersjant-Roorda MC, de Boer R, Meijer P, Spielman D, Kluft C. In low-dose oral contraceptives containing 20 mcg or 30 mcg ethinylestradiol, gestodene is associated with a lower increase in coagulant factor VII than in desogestrel. Gynecol Endocrinol 1996; 10 (Suppl. 02) 133-5.
• 19 Norris LA, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol 1996; 103: 261-7.
• 20 Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269 (29) 18735-8.
• 21 Schlit AF, Grandjean P, Donnez J, Lavenne E. Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives. Contraception 1995; 51: 53-8.
• 22 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-703.
• 23 Simioni P, Tormene D, Manfrin D, Gavasso S, Luni S, Stocco D, Girolami A. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 1998; 103 (04) 1045-50.
• 24 Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 1996; 76 (05) 729-34.
• 25 Bloemenkamp KW, Helmerhorst FM, Dersjant-Roorda MC, de Boer R, Meyer P, Spielman D, Kluft C. A comparative clinical investigation of two low-dose oral contraceptives containing either 75 mcg gestodene or 150 mcg desogestrel combined with 20 mcg ethinyl estradiol: effect on hemostasis, lipid metabolism and carbohydrate metabolism. Gynecol Endocrinol 1998; 12 (Suppl) 21-30.
• 26 Levi M, Middeldorp S, Buller HR. Oral contraceptives and hormonal replacement therapy cause an imbalance in coagulation and fibrinolysis which may explain the increased risk of venous thromboembolism. Cardiovascular Research 1999; 41 (01) 21-4.
• 27 Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998; 80: 382-7.
• 28 Bloemenkamp KM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Int Med 2000; 160 (01) 49-52.
• 29 Tans G, Curvers J, Middeldorp S, Thomassen MCLGD, Meijers JCM, Prins MH, Bouma BN, Büller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
• 30 Meijers JCM, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by en enhanced factor XIindependent down regulation of fibrinolysis A randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 84: 9-14.